Drug Trial Radar · NCT05283720
A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma
Last checked: Nov 19, 2026Latest source record: Jul 7, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
264
Actual
Start
Jun 14, 2022
Primary completion
Nov 2032
Study completion Nov 2032
Sponsor
- Lead sponsor
- GenmabIndustry
- Sponsor type
- Industry
- Collaborators
- AbbVie
- First posted
- Mar 17, 2022
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
B-cell Lymphoma is an aggressive and rare cancer of a type of immune cell (a white blood cell responsible for fighting infections). The purpose of this study is to assess the safety and tolerability of epcoritamab in combination with anti-neoplastic agents in adult participants with Non-Hodgkin lymphoma (NHL). Adverse events and change in disease activity will be assessed. Epcoritamab is an investigational drug being developed for the treatment of NHL. Study doctors put the participants in groups called treatment arms. The combination of epcoritamab with anti-neoplastic agents will be explored. Each treatment arm receives a different treatment combination depending on eligibility. Approximately 496 adult participants with NHL will be enrolled in 100 sites globally. In both the dose escalation and dose expansion arms participants will receive subcutaneous (SC) epcoritamab in 28 day, 21 day, or 56 day cycles dependent on the arm in combination with the anti-neoplastic agents described below: 1: Oral lenalidomide in participants (PPTS) with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL); 2: Oral ibrutinib and oral lenalidomide in PPTS with R/R DLBCL; 3: Intravenous (IV) polatuzumab vedotin, IV rituximab, IV cyclophosphamide, IV doxorubicin hydrochloride (HCl), and oral prednisone (pola-R-CHP) in PPTS with newly diagnosed treatment-naïve DLBCL, or completion of treatment in 3B; 4: Oral CC-99282 in PPTS with R/R DLBCL; 5: Oral CC-99282 in PPTS with R/R follicular lymphoma (FL); 6A: Oral ibrutinib in PPTS with R/R mantle cell lymphoma (MCL). There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at an approved institution (hospital or clinic). The effect of the treatment will be frequently checked by medical assessments, blood tests, questionnaires and side effects.
Conditions
- Non-Hodgkin Lymphoma
Interventions
EpcoritamabDrug
Subcutaneous Injection (SC)
LenalidomideDrug
Oral; Capsule
IbrutinibDrug
Oral; Capsule
RituximabDrug
Intravenous (IV); Injection
CyclophosphamideDrug
IV; Injection
Doxorubicin Hydrochloride [HCl]Drug
IV; Injection
PrednisoneDrug
Oral; Tablet
Polatuzumab VedotinDrug
IV; Injection
CC-99282Drug
Oral; Capsule
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants with Dose-Limiting Toxicities (DLT)Time frame: Up to Approximately 5 Years
Locations
76 sites in 13 countries. Site status is shown where the registry gives one.
The University of Arizona Cancer Center - North Campus /ID# 242219
Tucson, Arizona
Yale University School of Medicine /ID# 242089
New Haven, Connecticut
Christiana Care Health Service /ID# 242301
Newark, Delaware
Tampa General Hospital /ID# 246748
Tampa, Florida
Winship Cancer Institute of Emory University /ID# 242153
Atlanta, Georgia
University of Maryland, Baltimore /ID# 242218
Baltimore, Maryland
Alliance for Multispecialty Research (AMR) - Kansas City /ID# 242144
Kansas City, Missouri
Northwell Health - Monter Cancer Center /ID# 245435
Lake Success, New York
Icahn School of Medicine at Mount Sinai /ID# 242123
New York, New York
Novant Health Presbyterian Medical Center /ID# 242148
Charlotte, North Carolina
East Carolina University - Brody School of Medicine /ID# 242506
Greenville, North Carolina
Novant Health Forsyth Medical Center /ID# 242198
Winston-Salem, North Carolina
Thomas Jefferson University Hospital /ID# 242077
Philadelphia, Pennsylvania
Fox Chase Cancer Center /ID# 242106
Philadelphia, Pennsylvania
Thompson Cancer Survival Ctr /ID# 242150
Knoxville, Tennessee
Joe Arrington Cancer Research /ID# 242226
Lubbock, Texas
Swedish Medical Center - Seattle /ID# 242269
Seattle, Washington
MultiCare Institute for Research and Innovation /ID# 242127
Tacoma, Washington
Beijing Cancer Hospital /ID# 252303
Beijing, Beijing Municipality, China
Fudan University Shanghai Cancer Center /ID# 252292
Shanghai, Shanghai Municipality, China
Fakultni nemocnice Hradec Kralove - Sokolska /ID# 241722
Hradec Králové, Czechia
Fakultni Nemocnice Brno - Jihlavska /ID# 242683
Brno, Brno-mesto, Czechia
Fakultni Nemocnice Ostrava /ID# 242684
Ostrava, Ostrava-mesto, Czechia
Vseobecna Fakultni nemocnice v Praze /ID# 242685
Prague, Praha 17, Czechia
Aarhus Universitetshospital - Skejby /ID# 242670
Aarhus, Central Jutland, Denmark
Aalborg University Hospital /ID# 242734
Aalborg, North Denmark, Denmark
Hopital Saint-Louis /ID# 242336
Paris, France
CHU Clermont-Ferrand /ID# 242344
Clermont, Auvergne-Rhône-Alpes, France
CHU de Rennes - PONTCHAILLOU /ID# 242339
Rennes, Brittany Region, France
Hopital Pitie Salpetriere /ID# 242343
Paris, Île-de-France Region, France
Centre Hospitalier Regional Universitaire de Nancy - Hopitaux de Brabois /ID# 242342
Vandœuvre-lès-Nancy, Meurthe-et-Moselle, France
CHRU Lille - Hopital Claude Huriez /ID# 242335
Lille, Nord, France
IUCT Oncopole /ID# 242340
Toulouse, Occitanie, France
Hopitaux Universitaires Henri Mondor - Hopital Henri Mondor /ID# 242337
Créteil, Paris, France
Centre Hospitalier Universitaire de Nantes, Hotel Dieu -HME /ID# 242345
Nantes, Pays de la Loire Region, France
HCL - Hopital Lyon Sud /ID# 242349
Pierre-Bénite, Rhone, France
Universitaetsklinikum Ulm /ID# 244265
Ulm, Baden-Wurttemberg, Germany
Klinikum Augsburg /ID# 244523
Augsburg, Bavaria, Germany
Universitaetsklinikum Regensburg /ID# 244517
Regensburg, Bavaria, Germany
Universitaetsklinikum Wuerzburg /ID# 245453
Würzburg, Bavaria, Germany
Showing 40 of 76 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.